References
- Gollob MH, COVID-19, Clinical Trials and QT-Prolonging Prophylactic
Therapy in Healthy Subjects: First, Do No Harm, Journal of the
American College of Cardiology (2020), doi:
https://doi.org/10.1016/j.jacc.2020.05.008.
- Mercuro NJ, Yen CF, Shim DJ, Maher TR, McCoy CM, Zimetbaum PJ, Gold
HS. Risk of QT Interval Prolongation Associated With Use
of Hydroxychloroquine With or Without Concomitant Azithromycin Among
Hospitalized Patients Testing Positive for Coronavirus Disease 2019
(COVID-19). JAMA Cardiol. 2020 May 1:
e201834. doi: 10.1001/jamacardio.2020.1834
- Bessière F, Roccia H, Delinière A, Charrière R, Chevalier P, Argaud L,
Cour M. Assessment of QT Intervals in a Case Series of Patients
With Coronavirus Disease 2019 (COVID-19) Infection Treated
With Hydroxychloroquine Alone or in Combination With Azithromycin in
an Intensive Care Unit. JAMA Cardiol. 2020 May 1 :
e201787. doi: 10.1001/jamacardio.2020.1787
- Saleh M, Gabriels J, Chang D, Kim BS, Mansoor A, Mahmood E, Makker P,
Ismail H, Goldner B, Willner J, Beldner S, Mitra R, John R, Chinitz J,
Skipitaris N, Mountantonakis S, Epstein LM. The Effect of Chloroquine,
Hydroxychloroquine and Azithromycin on the Corrected QT Interval in
Patients With SARS-CoV-2 Infection. Circ Arrhythm Electrophysiol 2020
Apr 29. doi: 10.1161/CIRCEP.120.008662. PMID: 32347743 DOI:
10.1161/CIRCEP.120.008662
- Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J,
Weinberg P, Kirkwood J, Muse A, DeHovitz J, Blog DS, Hutton
B, Holtgrave DR, Zucker HA. Association of Treatment With
Hydroxychloroquine or Azithromycin With In-Hospital Mortality in
Patients With COVID-19 in New York State. JAMA; 2020 May 11;e208630.
doi: 10.1001/jama.2020.8630. Online ahead of print.
- Drew BJ, Ackerman MJ, Funk M et al. Prevention of torsade de pointes
in hospital settings: a scientific statement from the American Heart
Association and the American College of Cardiology Foundation.
Circulation 2010;121:1047-60.